» Articles » PMID: 9669786

Effect of Excessive Weight Gain with Intensive Therapy of Type 1 Diabetes on Lipid Levels and Blood Pressure: Results from the DCCT. Diabetes Control and Complications Trial

Overview
Journal JAMA
Specialty General Medicine
Date 1998 Jul 21
PMID 9669786
Citations 144
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Intensive treatment of type 1 diabetes results in greater weight gain than conventional treatment.

Objective: To determine the effect of this weight gain on lipid levels and blood pressure.

Design: Randomized controlled trial; ancillary study of the Diabetes Control and Complications Trial (DCCT).

Setting: Twenty-one clinical centers.

Participants: The 1168 subjects enrolled in DCCT with type 1 diabetes who were aged 18 years or older at baseline.

Intervention: Randomized to receive either intensive (n = 586) or conventional (n = 582) diabetes treatment with a mean follow-up of 6.1 years.

Main Outcome Measures: Plasma lipid levels and blood pressure in each treatment group categorized by quartile of weight gain.

Results: With intensive treatment, subjects in the fourth quartile of weight gain had the highest body mass index (BMI) (a measure of weight adjusted for height), blood pressure, and levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B compared with the other weight gain quartiles with the greatest difference seen when compared with the first quartile (mean values for the highest and lowest quartiles: BMI, 31 vs 24 kg/m2; blood pressure, 120/77 mm Hg vs 113/73 mm Hg; triglyceride, 0.99 mmol/L vs 0.79 mmol/L [88 mg/dL vs 70 mg/dL]; LDL-C, 3.15 mmol/L vs 2.74 mmol/L [122 mg/dL vs 106 mg/dL]; and apolipoprotein B, 0.89 g/L vs 0.78 g/L; all P<.001). In addition, the fourth quartile group had a higher waist-to-hip ratio; more cholesterol in the very low density lipoprotein, intermediate dense lipoprotein, and dense LDL fractions; and lower high-density lipoprotein cholesterol and apolipoprotein A-I levels compared with the first quartile. Baseline characteristics were not different between the first and fourth quartiles of weight gain with intensive therapy except for a higher hemoglobin A1c in the fourth quartile. Weight gain with conventional therapy resulted in smaller increases in BMI, lipids, and systolic blood pressure.

Conclusions: The changes in lipid levels and blood pressure that occur with excessive weight gain with intensive therapy are similar to those seen in the insulin resistance syndrome and may increase the risk of coronary artery disease in this subset of subjects with time.

Citing Articles

Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults.

Infante M, Silvestri F, Padilla N, Pacifici F, Pastore D, Pinheiro M J Clin Med. 2025; 14(4).

PMID: 40004833 PMC: 11856673. DOI: 10.3390/jcm14041303.


Trends in BMI in Latin American Children With New-Onset Type 1 Diabetes Over 3 Years.

Hirschler V, Molinari C, Andres M, Figueroa A, Femenia V, Pietropaolo G Clin Diabetes. 2025; 43(1):12-22.

PMID: 39829693 PMC: 11739364. DOI: 10.2337/cd24-0028.


Interventions Targeting Insulin Resistance in Patients with Type 1 Diabetes: A Narrative Review.

Herascu A, Avram V, Gaita L, Alexandra S, Reurean-Pintilei D, Timar B Medicina (Kaunas). 2025; 60(12.

PMID: 39768947 PMC: 11678706. DOI: 10.3390/medicina60122067.


Phase angle and body composition in long-term type 1 diabetes in adults: a comparative study in a Brazilian public reference outpatient clinic.

Fenner-Pena N, Fajardo V, Froes L, Carvalho P, Comim F, Sahade V Diabetol Metab Syndr. 2024; 16(1):269.

PMID: 39533433 PMC: 11559135. DOI: 10.1186/s13098-024-01485-8.


GLP-1 Receptor Agonists in Overweight and Obese Individuals With Type 1 Diabetes Using an Automated Insulin Delivery Device: A Real-World Study.

Holmager P, Christensen M, Norgaard K, Schmidt S J Diabetes Sci Technol. 2024; 19(2):286-291.

PMID: 39417493 PMC: 11571627. DOI: 10.1177/19322968241289438.


References
1.
Dorman J, LaPorte R, Kuller L, Cruickshanks K, Orchard T, Wagener D . The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes. 1984; 33(3):271-6. DOI: 10.2337/diab.33.3.271. View

2.
. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care. 1995; 18(11):1415-27. DOI: 10.2337/diacare.18.11.1415. View

3.
Purnell J, Marcovina S, Hokanson J, Kennedy H, Cleary P, Steffes M . Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial. Diabetes. 1995; 44(10):1218-26. PMC: 2866034. DOI: 10.2337/diab.44.10.1218. View

4.
. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care. 1988; 11(7):567-73. DOI: 10.2337/diacare.11.7.567. View

5.
. Detection and management of lipid disorders in diabetes. American Diabetes Association. Diabetes Care. 1993; 16(5):828-34. DOI: 10.2337/diacare.16.5.828. View